New pill shows promise against Hard-to-Treat cancers
NCT ID NCT05490472
First seen Nov 12, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100101, China
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
-
Jilin Cancer Hospital
RECRUITINGChangchun, Jilin, 130000, China
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100101, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
University of Utah Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAB-2485 (Aurora A inhibitor, taken orally)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 102 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.